Extending Talquetamab Education Beyond the Hospital

Health care education initiatives at the University of California, San Francisco have expanded to include local oncologists and community centers as bispecific antibodies transition to outpatient administration. Samantha Shenoy, NP, MSN, and colleagues conduct education sessions for affiliated centers, focusing on managing talquetamab adverse effects, infection prevention, and recognizing treatment-related complications. These educational efforts are crucial as therapies move from academic medical centers to community practice settings.

Emergency department education represents a critical component of comprehensive care coordination, ensuring that emergency physicians can recognize and manage CRS and neurotoxicity when patients present with concerning symptoms. The educational initiatives extend to support groups, where health care providers present information about bispecific antibodies and expected adverse effects to help patients and families prepare for treatment experiences.

The systematic approach to education across multiple health care touchpoints—from community oncology centers to emergency departments to patient support groups—demonstrates the comprehensive planning required for safe bispecific antibody administration. This educational framework ensures that as these therapies become more widely available outside major cancer centers, health care providers throughout the continuum of care are prepared to recognize and manage treatment-related complications appropriately.